All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
NICE backs obinutuzumab plus bendamustine chemotherapy for patients with follicular lymphoma
By Emily Smith
Bookmark this article
The United Kingdom’s National Institute for Health and Clinical Excellence (NICE) has recommended National Health Service (NHS) funding for obinutuzumab in combination with bendamustine chemotherapy for patients with follicular lymphoma (FL). Patients with FL who have not responded to, or who have progressed up to six months after rituximab or rituximab-containing treatment, will now be able to receive the combination via the NHS, as opposed to funding from the Cancer Drugs Fund.
An updated analysis of the GADOLIN study, which compared obinutuzumab plus bendamustine versus bendamustine alone, found the combination regimen provided a progression-free survival benefit over bendamustine monotherapy in patients with indolent non-Hodgkin lymphoma, including FL.
- National Institute for Health and Clinical Excellence (NICE). Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab. https://www.nice.org.uk/guidance/ta629/chapter/1-Recommendations. Published May 13, 2020. Accessed May 13, 2020.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
60 votes - 49 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox